Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649)

被引：0
|
作者：
Lin, Daniel
Quan, Wenying
Garretson, Marne
Chirikov, Viktor
Chen, Clara
Singh, Prianka
Davis, Catherine
Sugarman, Ryan
机构：
[1] Thomas Jefferson Univ Hosp, Philadelphia, PA USA
[2] OPEN Hlth, Bethesda, MD USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4044
引用
收藏
页数：1
相关论文
共 38 条
  • [21] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Wang, Rui
    Sullivan, Kendall
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 353 - 353
  • [22] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Hu, Nan
    McCraith, Stephen
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 392 - 392
  • [23] Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses
    Janjigian, Yelena Y.
    Shitara, Kohei
    Ajani, Jaffer
    Moehler, Markus
    Yao, Jin
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Schenker, Michael
    Yanez, Patricio
    Kowalyszyn, Ruben
    Karamouzis, Michalis
    Zander, Thomas
    Feeney, Kynan
    Elimova, Elena
    Nathani, Raheel
    Novosiadly, Ruslan
    Lei, Ming
    CANCER RESEARCH, 2023, 83 (08)
  • [24] First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Cleary, James M.
    Elimova, Elena
    Karamouzis, Michalis
    Bruges, Ricardo
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshi
    Tehfe, Mustapha
    Zander, Thomas
    Kowalyszyn, Ruben
    Pazo-Cid, Roberto
    Schenker, Michael
    Feeny, Kynan
    Wang, Rui
    Lei, Ming
    Chen, Clara
    Nathani, Raheel
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2012 - 2020
  • [25] Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
    Daniel Lin
    Hiep Nguyen
    Ruchit Shah
    Yao Qiao
    John Hartman
    Ryan Sugarman
    Gastric Cancer, 2023, 26 : 415 - 424
  • [26] Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
    Lin, Daniel
    Nguyen, Hiep
    Shah, Ruchit
    Qiao, Yao
    Hartman, John
    Sugarman, Ryan
    GASTRIC CANCER, 2023, 26 (03) : 415 - 424
  • [27] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Results of nivolumab plus chemotherapy (NIVO plus chemo) versus chemo from CheckMate 649
    Elimova, Elena
    Wyrwicz, Lucjan
    Blum, Steven I.
    Xiao, Hong
    Li, Mingshun
    Kondo, Kaoru
    Davenport, Eric
    Wang, Jinyi
    Hunter, Shannon
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [28] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
    Moehler, M.
    Elimova, E.
    Blum, S., I
    Xiao, H.
    Davenport, E.
    Wang, J.
    Hunter, S.
    Li, M.
    Kondo, K.
    Wyrwicz, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 214 - 215
  • [29] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649.
    Wyrwicz, Lucjan
    Elimova, Elena
    Blum, Steven I.
    Xiao, Hong
    Davenport, Eric
    Wang, Jinyi
    Hunter, Shannon
    Li, Mingshun
    Kondo, Kaoru
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/ gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
    Elimova, Elena
    Wyrwicz, Lucjan
    Chen, Clara
    Blum, Steven Michael
    Davenport, Eric
    Wang, Jinyi
    Kondo, Kaoru
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
1234